Continuation Study for Latozinemab
Public ClinicalTrials.gov record NCT06111014. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
Study identification
- NCT ID
- NCT06111014
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 17 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2023
- Primary completion
- Aug 31, 2025
- Completion
- Jan 6, 2026
- Last update posted
- Jan 20, 2026
2023 – 2026
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dignity Health - Arizona | Phoenix | Arizona | 85013 | — |
| Mayo Comprehensive Cancer Center - PPDS | Rochester | Minnesota | 55905 | — |
| Irving Institute for Clinical and Translational Research | New York | New York | 10032 | — |
| University of Cincinnati Gardner Neuroscience Institute | Cincinnati | Ohio | 45219 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
Recently updated Neurodegenerative Diseases trials
Other public records listing Neurodegenerative Diseases. Sorted by last update posted; newest first. Not a recommendation.
- NCT07758114: Prenatal Education on Environmental Exposures During Pregnancy Study (PEEPS) Recruiting
- NCT04838301: Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease Active, not recruiting
- NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) Active, not recruiting
- NCT05354622: Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) Recruiting
- NCT05741853: Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia Recruiting
- NCT05245903: Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06111014, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06111014 live on ClinicalTrials.gov.